Pharmaceuticals, Biotechnology and Life Sciences
The consumption levels are anticipated to rise exponentially over the forecast period. The companies and government organizations are working collaboratively to bridge the gap between supply and demand.
The U.S. Food and Drug Administration (FDA) has approved Marathon Pharmaceuticals’s Emflaza (deflazacort) tablets and oral suspension to treat patients age 5 years and older with Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes progressive muscle deterioration and weakness.
The fourth quarter of 2016, global net sales of Praluent were $41 million, compared to $7 million in the fourth quarter of 2015.
The Global Pulmonary Drug Delivery Devices Market demonstrates a high degree of competition between GlaxoSmithKline Plc, Boehringer Ingelheim GmbH, AstraZeneca Plc, Teva Pharmaceutical Industries Ltd., and Merck & Co. Inc.
Ablynx will present additional data from the Phase IIb RA combination study of its anti-IL-6R Nanobody, vobarilizumab, at the Annual Scientific Meeting of the Canadian Rheumatology Association, being held from 8-11 February 2017 in Ottawa, Ontario (Canada).
Tetraphase Pharmaceuticals Inc Chief Executive Guy Macdonald said annual sales of the company’s lead experimental antibiotic for serious bacterial infections could climb as high as $700 million if approved.
Sanofi and Regeneron will continue marketing, selling and manufacturing Praluent in the United States (U.S.) during their appeal on Amgen’s patent claims.
U.S. Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) does not plan to hold an Advisory Committee meeting with Portola Pharmaceuticals for New Drug Application (NDA) for betrixaban, Portola said on Wednesday.
Eli Lilly has updated its Trulicity label to now include use in combination with basal insulin for adults with type 2 diabetes.
US Government Services Administration (GSA) has awarded MDxHealth to supply Department of Veterans Affairs (VA) with ConfirmMDx for Prostate Cancer.